These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16461958)

  • 1. Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
    Ann Intern Med; 2006 Feb; 144(3):I33. PubMed ID: 16461958
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
    Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
    Whaley-Connell A; Sowers JR
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):884-6. PubMed ID: 22595830
    [No Abstract]   [Full Text] [Related]  

  • 6. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
    Moes AD; Hesselink DA; van den Meiracker AH; Zietse R; Hoorn EJ
    Am J Kidney Dis; 2017 Jun; 69(6):796-804. PubMed ID: 28259499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Muheim L
    Praxis (Bern 1994); 2017; 106(5):271-272. PubMed ID: 28253804
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
    Whittle J; Lynch AI; Tanner RM; Simpson LM; Davis BR; Rahman M; Whelton PK; Oparil S; Muntner P
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):471-80. PubMed ID: 26912544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 15. [What are the sequelae of the ALLHAT Study?].
    Vetter W;
    Dtsch Med Wochenschr; 2003 Mar; 128(13):687. PubMed ID: 12698959
    [No Abstract]   [Full Text] [Related]  

  • 16. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
    Davis BR; Arnett DK; Boerwinkle E; Ford CE; Leiendecker-Foster C; Miller MB; Black H; Eckfeldt JH
    Pharmacogenomics J; 2007 Apr; 7(2):112-22. PubMed ID: 16702981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
    Zhang X; Lynch AI; Davis BR; Ford CE; Boerwinkle E; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    PLoS One; 2012; 7(3):e34217. PubMed ID: 22470539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed messages on blood pressure goals.
    Chobanian AV
    Hypertension; 2011 Jun; 57(6):1039-40. PubMed ID: 21555679
    [No Abstract]   [Full Text] [Related]  

  • 19. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension.
    Heckman GA; Psaty BM
    ACP J Club; 2003; 139(3):A15; author reply A15. PubMed ID: 14594435
    [No Abstract]   [Full Text] [Related]  

  • 20. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
    Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.